AEterna Zentaris
42
0
0
37
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
11.9%
5 terminated/withdrawn out of 42 trials
88.1%
+1.6% vs industry average
24%
10 trials in Phase 3/4
19%
7 of 37 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (42)
A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is
Role: lead
Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
Role: collaborator
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Role: collaborator
Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.
Role: lead
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Role: lead
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Role: lead
Study of Perifosine + Capecitabine for Colon Cancer Patients
Role: lead
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Role: lead
Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma
Role: lead
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia
Role: lead
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
Role: lead
A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies
Role: lead
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
Role: lead
Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia
Role: lead
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
Role: lead
Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas
Role: lead
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
Role: lead
Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
Role: lead
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
Role: lead
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Role: lead